Eugene K. Lee
Expertise in
20
conditions

Dr. Eugene K. Lee

Oncology
4000 Cambridge Street, 
Kansas City, KS 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
20
conditions
4000 Cambridge Street, 
Kansas City, KS 

Overview

Eugene Lee is an Oncologist practicing medicine in Kansas City, Kansas.

Dr. Lee is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Dr. Lee is board certified in American Board Of Urology, Urology - 2015. He is actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 8 clinical trials. Dr. Lee is currently accepting new patients.

Specialties

Oncology

Licenses

Urology in KS

Board Certifications

American Board Of Urology, Urology - 2015

Fellowships

The University of Texas MD Anderson Cancer Center, Urologic Oncology, 2013

Hospital Affiliations

University Of Kansas Health System Olathe Hospital
University Of Kansas Hospital
Cameron Regional Medical Center
Stormont Vail Hospital

Languages Spoken

English
Korean

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

The University of Kansas Hospital
4000 Cambridge Street, Kansas City, KS 66160
Other Locations
Westwood Medical Pavilion
2650 Shawnee Mission Parkway, Westwood, KS 66205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Blue Light Cystoscopy With Cysview® Registry
Blue Light Cystoscopy With Cysview® Registry
Enrollment Status: Recruiting
Publish Date: December 18, 2025
Intervention Type: Device, Drug
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Biological
Study Drugs: CG0070, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 3
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 23, 2026
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: ALT-803, Bacillus Calumette-Guerin
Study Phase: Phase 2/Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
View 7 Less Clinical Trials

50 Total Publications

Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial.
Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial.
Journal: JAMA network open
Published: July 20, 2026
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (0.1 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Holzbeierlein is an Oncologist practicing medicine in Kansas City, Kansas. Dr. Holzbeierlein is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Holzbeierlein is board certified in American Board Of Urology, Urology - 2004. Dr. Holzbeierlein is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Saint Luke's Cancer Specialists-Plaza

4401 Wornall Rd, 
Kansas City, MO 
 (1.1 miles away)
816-932-3300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Samuel Goldlust is an Oncologist practicing medicine in Kansas City, Missouri. Dr. Goldlust is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Goldlust is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
 (2.5 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tara Lin is an Oncologist practicing medicine in Fairway, Kansas. Dr. Lin is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Colonoscopy. Dr. Lin is board certified in American Board Of Internal Medicine, Medical Oncology - 2005. Dr. Lin is currently accepting new patients.

Frequently Asked Questions about Dr. Eugene K. Lee

How do I make an appointment with Dr. Eugene K. Lee?

You can book an appointment with Dr. Eugene K. Lee by calling their office at 913-588-1227. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Eugene K. Lee a top-rated expert for Bladder Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Eugene K. Lee is classified as an Elite expert for Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Eugene K. Lee specialize in?

While Dr. Eugene K. Lee is a Oncology, they have specific expertise in Bladder Cancer, Non-Muscle Invasive Bladder Cancer, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Eugene K. Lee participate in research or clinical trials?

Yes. Dr. Eugene K. Lee has published 50 articles and abstracts on conditions like Bladder Cancer. You can view a list of Dr. Eugene K. Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Eugene K. Lee accept my insurance?

Dr. Eugene K. Lee accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 913-588-1227 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 8 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile